SCHEMBL7710869

SCHEMBL7710869

CC1Oc2ccc(C(Cc3ccccc3F)NC(=O)OC(C)(C)C)cc2N=C1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
PTPN1 P18031 1/20 0.38
SCN9A Q15858 11/20 0.38
ALDH1A1 P00352 5/20 0.35
KDM4E B2RXH2 2/20 0.35
RCE1 Q9Y256 1/20 0.35
HPGD P15428 3/20 0.35
HTT P42858 3/20 0.35
NPSR1 Q6W5P4 3/20 0.35
JAK2 O60674 2/20 0.35
XBP1 P17861 2/20 0.35
TP53 P04637 1/20 0.35
MAPK1 P28482 1/20 0.35
ATM Q13315 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PLA2G1B P04054 1/20 0.35
MAPT P10636 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
S1PR3 Q99500 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704992 0.90 ALDH1A1 (0.35) CTSKSCN9AALDH1A1KDM4ERCE1
SCHEMBL7704912 0.88 ALDH1A1 (0.45) CTSSCTSKALDH1A1HPGDHTT
SCHEMBL7713371 0.87 NPSR1 (0.37) ALDH1A1KDM4ERCE1HPGDHTT
SCHEMBL7713363 0.87 HPGD (0.41) CTSSCTSKSCN9AALDH1A1KDM4E
SCHEMBL7708356 0.86 CTSS (0.41) CTSSCTSKSCN9AALDH1A1HPGD
SCHEMBL7711250 0.86 ALDH1A1 (0.46) CTSSCTSKSCN9AALDH1A1HPGD
SCHEMBL7711369 0.84 ALDH1A1 (0.37) CTSSCTSKALDH1A1KDM4ERCE1
SCHEMBL7708019 0.84 SMN1; SMN2 (0.42) ALDH1A1KDM4ERCE1HPGDHTT
SCHEMBL7708193 0.83 ALDH1A1 (0.38) CTSSCTSKALDH1A1KDM4ERCE1
SCHEMBL7704969 0.83 ALDH1A1 (0.36) ALDH1A1HPGDHTTNPSR1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed